At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2,080 enrolled
Drug / intervention
BEA 2180 BR +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multinational, Randomised, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison Over 24 Weeks of Three Doses (50µg, 100µg, 200µg) of BEA 2180 BR to Tiotropium 5µg, Delivered by the Respimat Inhaler and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 2 clinical trial evaluating BEA 2180 BR, Tiotropium Bromide, and 1 other intervention for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 2,080 participants across 178 sites in 10 countries.
Detailed Summary
The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives include comparing the effects on dyspnea and health status.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesCanada, Germany, Hungary, Mexico, Poland, Russia, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedSep 2007
Primary CompletionMay 2009
TodayJul 2026
First PostedSep 14, 2007
Enrollment StartSep 6, 2007
Primary CompletionMay 5, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.8 years ago
Interventions
BEA 2180 BRdrug
Solution
Tiotropium Bromidedrug
Solution
Placebodrug
Solution